Omeros Reports OMS103HP Phase 3 Clinical Trial Results - FierceBiotech

zlatkopaisley1275.blogspot.com

Omeros Reports OMS103HP Phase 3 Clinical Trial Results FierceBiotech SEATTLE, Dec. 27, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported results from its first pivotal Phase 3 clinical trial evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery. In this multicenter ... Omeros misses target in clinical trial The Seattle Times UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Omeros ... Benzinga Canaccord Genuity Sets Omeros Corp Price Target at $13.00 (OMER) Jags Report  »